Understanding our love affair with p-chlorophenyl: Present day implications from historical biases of reagent selection

Journal of Medicinal Chemistry

Volumn 58, Issue 5, 2015, Pages 2390-2405

  Brown, Dean G ^a   Gagnon, Moriah M ^a   Boström, Jonas ^b  

^a ASTRAZENECA   (United Kingdom)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

4 CHLOROPHENOL; PHENYL GROUP; CHLORINATED HYDROCARBON; DYES, REAGENTS, INDICATORS, MARKERS AND BUFFERS; PHENOL DERIVATIVE;

ARTICLE; CONFORMATIONAL TRANSITION; DATA BASE; HYDROPHOBICITY; SAMPLE SIZE; SELECTION BIAS; SUBSTITUTION REACTION; SUZUKI REACTION; SYNTHESIS; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DESIGN; DRUG DEVELOPMENT; HUMAN; STANDARDS; STRUCTURE ACTIVITY RELATION;

DRUG DESIGN; DRUG DISCOVERY; HUMANS; HYDROCARBONS, CHLORINATED; INDICATORS AND REAGENTS; MOLECULAR STRUCTURE; PHENOLS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84924709740     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm501894t     Document Type: Article

References (43)

1. Boström, J.; Falk, N.; Tyrchan, C. Exploiting personalized information for reagent selection in drug design Drug Discovery Today 2011, 16, 182-187
2. Lajiness, M. S.; Maggiora, G. M.; Shanmugasundaram, V. Assessment of consistency of medicinal chemists in reviewing sets of compounds J. Med. Chem. 2004, 47, 4891-4896
3. Accelrys Available Chemicals Directory (ACD), version 2014.2. http://accelrys.com/products/pdf/available-chemicals-directory.pdf.
4. Varkonyi, O.; Hoppe, C.; Muresan, S. IBEX-access and exploit SAR data from patents and journals. Presented at ChemAxon UGM, Budapest, Hungary, June 7-8, 2008; http://www.chemaxon.com/forum/viewpost16936.html#16936.
5. Bernstein, F. C.; Koetzle, T. F.; Williams, G. J. B.; Meyer, E. F., Jr.; Brice, M. D.; Rodgers, J. R.; Kennard, O.; Schimanouchi, T.; Tasumi, M. The Protein Data Bank: A computer-based archival file for macromolecular structures J. Mol. Biol. 1977, 112, 535-542
6. http://www.rcsb.org/ (accessed Nov 8, 2014).
7. Gaulton, A.; Bellis, L. J.; Bento, A. P.; Chambers, J.; Davies, M.; Hersey, A.; Light, Y.; McGlinchey, S.; Michalovich, D.; Al-Lazikani, B.; Overington, J. P. ChEMBL: A large-scale bioactivity database for drug discovery Nucleic Acids Res. 2012, 40, D1100-D1107
8. Pihan, E.; Colliandre, L.; Guichou, J.-F.; Douguet, D. e-Drug3D: 3D structure collections dedicated to drug repurposing and fragment-based drug design Bioinformatics 2012, 28, 1540-1541
9. http://chemoinfo.ipmc.cnrs.fr/MOLDB/index.html.
10. Topliss, J. G. Utilization of operational schemes for analog synthesis in drug design J. Med. Chem. 1972, 15, 1006-1011
11. Beak, P.; Kerrick, S. T.; Gallagher, D. J. Directed lithiations: The effect of varying directing group orientation on competitive efficiencies for a series of tertiary amide, secondary amide, and alkoxide directed ortho lithiations J. Am. Chem. Soc. 1993, 115, 10628-10636
12. Lovering, F.; Bikker, J.; Humblet, C. Escape from flatland: Increasing saturation as an approach to improving clinical success J. Med. Chem. 2009, 52, 6752-6756
13. Mun, J.; Jabbar, A. A.; Devi, N. S.; Yin, S.; Wang, Y.; Tan, C.; Culver, D.; Snyder, J. P.; Van Meir, E. G.; Goodman, M. M. Design and in vitro activities of N-alkyl-N-[(8-R 2,2-dimethyl-2 H-chromen-6-yl)methyl]heteroarylsulfonamides, novel, small molecules hypoxia inducible factor-1 pathway inhibitors and anticancer agents J. Med. Chem. 2012, 55, 6738-6750
14. Data were generated using SciFinder from Chemical Abstracts Service, a division of the American Chemical Society: http://www.cas.org/products/scifinder (accessed Oct 6, 2014).
15. Suzuki, A. Cross-coupling reactions of organoboranes: An easy way to construct C-C bonds (Nobel Lecture) Angew. Chem., Int. Ed. 2011, 50, 6723-6737
16. Lombardino, J. G.; Lowe, J. A., III. The role of medicinal chemist in drug discovery-then and now Nat. Rev. Drug Discovery 2004, 3, 853-862
17. O'Boyle, N. M.; Boström, J.; Sayle, R. A.; Gill, A. Using matched molecular series as a predictive tool to optimize biological activity J. Med. Chem. 2014, 57, 2704-2713
18. Leach, A. G.; Jones, H. D.; Cosgrove, D. A.; Kenny, P. A.; Ruston, L.; MacFaul, P.; Wood, J. M.; Colclough, N.; Law, B. Matched molecular pairs as a guide in the optimization of pharmaceutical properties: A study of aqueous solubility, plasma protein binding and oral exposure J. Med. Chem. 2006, 49, 6672-6682
19. Papadatos, G.; Alkarouri, M.; Gillet, V. J.; Willett, P.; Luscombe, C. N.; Bravi, G.; Richmond, N. J.; Pickett, S. D.; Hussain, J.; Pritchard, J. M.; Cooper, A. W. J.; Macdonald, S. J. F. Lead optimization using matched molecular pairs: Inclusion of contextual information for enhanced prediction of hERG inhibition, solubility and lipophilicity J. Chem. Inf. Model. 2010, 50, 1872-1886
20. Kramer, C.; Fuchs, J. E.; Whitebread, S.; Gedeck, P.; Liedl, K. R. Matched molecular pair analysis: Significance and the impact of experimental uncertainty J. Med. Chem. 2014, 57, 3786-3802
21. Hajduk, P. J.; Sauer, D. R. Statistical analysis of the effects of common chemical substituents on ligand potency J. Med. Chem. 2008, 51, 553-564
22. McMahon, R. E. Microsomal dealkylation of drugs J. Pharm. Sci. 1966, 55, 457-466
23. Böhm, H.-J.; Banner, D.; Bendals, S.; Kansy, M.; Kuhn, B.; Müller, K.; Obst-Sander, U.; Stahl, M. Fluorine in medicinal chemistry ChemBioChem 2004, 5, 637-643
24. Flanagan, J. U.; Atwell, G. J.; Heinrich, D. M.; Brooke, D. G.; Silva, S.; Rigoreau, L. J.; Trivier, E.; Turnbull, A. P.; Raynham, T.; Jamieson, S. M.; Denny, W. A. Morphoylureas are a new class of potent and selective inhibitors of the type 5-b-hydroxysteroid dehydrogenase (AKR1C3) Bioorg. Med. Chem. 2014, 22, 967-977
25. He, L.; Zhang, L.; Liu, X.; Zheng, M.; Li, H.; Yu, K.; Chen, K.; Shen, X.; Jiang, H.; Liu, H. Discovering potent inhibitors against the beta-hydroxyacyl-acyl carrier protein dehydratase (FabZ) of Helicobacter pylori: structure-based design, synthesis, bioassay and crystal structure determination J. Med. Chem. 2009, 52, 2465-2481
26. Hardegger, L. A.; Kuhn, B.; Spinnler, B.; Anselm, L.; Ecabert, R.; Stihle, M.; Gsell, B.; Thoma, R.; Diez, J.; Benz, J.; Plancher, J.-M.; Hartmann, G.; Banner, D. W.; Haap, W.; Diederich, F. Systematic investigation of halogen bonding in protein-ligand interactions Angew. Chem., Int. Ed. 2011, 50, 314-318
27. Cole, D. C.; Olland, A. M.; Jacob, J.; Brooks, J.; Bursavich, M. G.; Czerwinski, R.; Declerq, C.; Johnson, M.; Joseph-McCarthy, D.; Ellingboe, J. W.; Lin, L.; Nowak, P.; Presman, E.; Strand, J.; Tam, A.; Williams, C. M. M.; Yao, S.; Tsao, D. H. H.; Fitz, L. J. Identification and characterization of acidic mammalian chitinase inhibitors J. Med. Chem. 2010, 53, 6122-6128
28. Sugishima, M.; Higashimoto, Y.; Oishi, T.; Takahashi, H.; Sakamoto, H.; Noguchi, M.; Fukuyama, K. X-ray crystallographic and biochemical characterization of the inhibitory action of an imidazole-dioxolane compound onheme oxygenase Biochemistry 2007, 46, 1860-1867
29. La, D. S.; Belzile, J.; Bready, J. V.; Coxon, A.; Demelfi, T.; Doerr, N.; Estrada, J.; Flynn, J. C.; Flynn, S. R.; Graceffa, R. F.; Harriman, S. P.; Larrow, J. F.; Long, A. M.; Martin, M. W.; Morrison, M. J.; Patel, V. F.; Roveto, P. M.; Wang, L.; Weiss, M. M.; Whittington, D. A.; Teffera, Y.; Zhao, Z.; Polverino, A. J.; Harmange, J. C. Novel 2,3-dihydro-1,4-benzoxazines as potent and orally bioavailable inhibitors of tumor-driven angiogenesis J. Med. Chem. 2008, 51, 1695-1705
30. Auffinger, P.; Hays, F. A.; Westhof, E.; Ho, P. S. Halogen bonding in biological molecules Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 16789-16794
31. Bissantz, C.; Kuhn, B.; Stahl, M. A medicinal chemist's guide to molecular interactions J. Med. Chem. 2010, 53, 5061-5084
32. Beale, T. M.; Chudzinksi, M. G.; Sarwar, M. G.; Taylor, M. S. Halogen bonding in solution: thermodynamics and applications Chem. Soc. Rev. 2013, 42, 1667-1680
33. Lu, Y.; Shi, T.; Wang, Y.; Yang, H.; Yan, X.; Luo, X.; Jiang, H.; Zhu, W. Halogen-bonding-A novel interaction for rational drug design J. Med. Chem. 2009, 52, 2854-2862
34. Molecular Operating Environment (MOE), version 2013.08; Chemical Computing Group Inc. (1010 Sherbooke St. West, Suite 910, Montreal, Quebec, Canada, H3A 2R7), 2015. A custom script was provided by the Chemical Computing Group for the application MOE in order to quantify the solvent exposed area of a given substituent on a ligand when bound to solvent: substituent-sa.svl, Scientific Vector Language (SVL); e-mail, support@chemcomp.com.
35. Sugiyama, M.; Kawanabe, M. Machine Learning in Non-Stationary Environments: Introduction to Covariate Shift Adaptation; MIT Press: Cambridge, MA, U.S., 2012.
36. Nicholls, A. JCAMD special series: statistics and molecular modeling J. Comput.-Aided Mol. Des. 2014, 28, 885-886
37. Klekota, J.; Roth, F. P. Chemical substructures that enrich for biological activity Bioinformatics 2008, 24, 2518
38. Ertl, P. Cheminformatics analysis of organic substituents: identification of the most common substituents, calculation of substituent properties, and automatic identification of drug-like bioisosteric groups J. Chem. Inf. Comput. Sci. 2003, 43, 374
39. Sarma, A. R. P. J.; Kishan, K. V. R. Database systems for knowledge-based discovery. In Chemogenomics: Methods and Applications; Jacoby, E., Ed.; Methods in Molecular Biology, Vol. 575; Humana Press: New York, NY, 2009; pp 159-172.
40. GVK Biosciences Pvt. Ltd., Balanagar, Hyderabad, India. http://www.gvkbio.com (accessed Jan 8, 2015).
41. Matsy, version 1.0.17; NextMove Software Ltd.: Cambridge, U.K.; http://www.nextmovesoftware.com (accessed Jan 8, 2015).
42. Hussain, J.; Rea, C. Computationally efficient algorithm to identify matched molecular pairs (MMPs) in large data sets J. Chem. Inf. Model. 2010, 50, 339-348
43. OEChem Python Tool-Kit; OpenEye Scientific Software, Inc.: Santa Fe, NM, U.S.; http://www.eyesopen.com (accessed Dec 10, 2013).